Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ERBB3 T355I |
| Therapy | Fulvestrant + Lapatinib |
| Indication/Tumor Type | estrogen-receptor positive breast cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ERBB3 T355I | estrogen-receptor positive breast cancer | sensitive | Fulvestrant + Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, the combination therapy of Faslodex (fulvestrant) and Tykerb (lapatinib) resulted in a synergistic effect, demonstrating decreased cell proliferation and reduced colony formation of estrogen-receptor positive breast cancer cells expressing ERBB3 (HER3) T355I in culture (PMID: 29963236). | 29963236 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (29963236) | Activating HER3 mutations in breast cancer. | Full reference... |